<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01919866</url>
  </required_header>
  <id_info>
    <org_study_id>1075/01 PEI</org_study_id>
    <nct_id>NCT01919866</nct_id>
  </id_info>
  <brief_title>Safety Study of CD3/CD19 Depleted Haploidentical Stem Cells</brief_title>
  <official_title>Haploidentical Stem Cell Transplantation With CD3/CD19 Depleted Stem Cells in Pediatric Patients With Refractory Hematological and Oncological Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Children’s Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Children’s Hospital Tuebingen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Feasibility and toxicity of haploidentical transplantation of CD3/CD19 depleted stem cells in
      combination with a toxicity reduced conditioning regimen or with standard conditioning
      regimens according to underlying disease.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2004</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Engraftment rate and transplant related mortality</measure>
    <time_frame>365 days</time_frame>
    <description>engraftment rate will be evaluated by leukocyte counts in peripheral blood . Definition of engraftment: &gt;500 neutrophiles/µl blood. Transplant related mortality will be evaluated at day 100 and day 365 post transplant</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Graft versus Host disease and speed of immune reconstitution</measure>
    <time_frame>365 days</time_frame>
    <description>Incidence of acute and chronic GvHD will be evaluated according to Glucksberg criteria. Immune recovery will be evaluated by flow cytometry. Percentages and numbers of T, B and NK cells will be measured weekly until day 100, afterwards on day 180 and 365.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Acute Leukemias</condition>
  <condition>Aplastic Anemia</condition>
  <condition>Childhood Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Transplantation of CD3/CD19 depleted stem cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive a minimum dosage of 10x10E6/kg bodyweight CD3/CD19 depleted CD34+ stem cells. Maximum dosage of residual T cells will be 1x10E5/kg BW</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Transplantation of CD3/CD19 depleted stem cells</intervention_name>
    <arm_group_label>Transplantation of CD3/CD19 depleted stem cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with primary refractory or relapsed disease (including relapse after previous
             SCT and active disease)

          -  AML in complete remission of refractory

          -  MDS RAEB-t/secondary AML

          -  ALL

          -  CML

          -  Non-Hodgkin Lymphoma / Hodgkin Lymphoma

          -  non malignant diseases (aplastic anemia, thalassemia, SCID)

          -  relapsed Neuroblastoma

          -  relapsed soft tissue sarcoma (Rhabdomyosarcoma, Ewing sarcoma, PNET

          -  soft tissue sarcoma with primary bone metastases or bone marrow

          -  in whom no matched donor was available,

        Exclusion Criteria:

          -  &lt; 6 months after previous HSCT

          -  active cerebral seizure conditions

          -  massive progression of leukemias or solid tumours before planned trp.

          -  left ventricular ejection fraction &lt;25%

          -  creatinine clearance &lt;40ml/min before conditioning

          -  respiratory insufficiency with oxygen demand or DLCO &lt;30%

          -  Bilirubin &gt;4mg/dl, GOT/GPT &gt;400

          -  severe infection (HIV, Aspergillosis)

          -  pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Lang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Children’s Hospital Tuebingen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peter Lang, MD</last_name>
    <phone>+4970712981386</phone>
    <email>peter.lang@med.uni-tuebingen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rupert Handgretinger, MD</last_name>
    <phone>+4970712984744</phone>
    <email>rupert.handgretinger@med.uni-tuebingen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Children's Hospital</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Urban, MD</last_name>
      <email>christian.urban@medunigraz.at</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Children's Hospital</name>
      <address>
        <city>Halle</city>
        <zip>6120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Mauz-Körholz, MD</last_name>
      <email>christine.mauz-koerholz@medizin.uni-halle</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Zentrum für Kinderheilkunde</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Sauer, MD</last_name>
      <email>sauer.martin@mh-hannover.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Children's Hospital</name>
      <address>
        <city>Jena</city>
        <zip>7745</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernd Gruhn, MD</last_name>
      <email>bernd.gruhn@med.uni-jena.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Children's Hospital</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Peter Lang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 7, 2013</study_first_submitted>
  <study_first_submitted_qc>August 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2013</study_first_posted>
  <last_update_submitted>October 7, 2014</last_update_submitted>
  <last_update_submitted_qc>October 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Children’s Hospital Tuebingen</investigator_affiliation>
    <investigator_full_name>Peter Lang</investigator_full_name>
    <investigator_title>Prof. Dr. med.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Aplastic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

